Effects of Wild Thyme Extract on Overweight and Obesity
Key facts
- Who runs it
- Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental
- Where
- Spain1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Enrolling by invitation
- People taking part
- 53 people, planned
- Started
- 17 Sept 2026
- Expected to end
- 17 Sept 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Wild Thyme extract
- Placebo
- Record updated
- 16 November 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Body mass index (BMI) ≥25.0 kg/m² at screening
- Participants with overweight (BMI 25.0-29.9 kg/m²) or obesity (BMI ≥30.0 kg/m²)
- Stable body weight during the predefined period before screening
- Willingness to maintain usual dietary and physical activity habits throughout the intervention period
- Ability and willingness to provide fecal samples at the predefined study time points
- Ability to comply with study procedures and intervention requirements
- Ability to understand the study procedures and provide written informed consent
Who cannot take part
- Presence of established or clinically unstable cardiovascular disease. 3. Pregnancy or breastfeeding. 4. Clinical diagnosis of inflammatory bowel disease. 5. Clinical diagnosis of celiac disease. 6. Major gastrointestinal disease that may interfere with study outcomes. 7. Previous bariatric surgery
- Use of investigational drugs within the predefined washout period
- Use of probiotics, prebiotics, synbiotics, or other microbiome-modulating supplements during the predefined washout period
- Known allergy or hypersensitivity to Thymus species or any component of the study product or placebo
- Any medical condition that, in the investigator's opinion, may interfere with participant safety, study compliance, interpretation of results, or completion of study procedures
- Current participation in another interventional clinical trial
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Overweight and obesity are characterized by excessive or abnormal adiposity and are associated with an increased risk of metabolic dysfunction, chronic low-grade inflammation, and several chronic diseases. While overweight is not classified as a disease in itself, it represents an early stage in the continuum of excess adiposity and is associated with an increased risk of progression to obesity and the development of obesity-related metabolic complications. Therefore, early intervention during the overweight stage may represent a critical opportunity to prevent or delay disease progression to obesity. Increasing evidence indicates that the gut microbiome plays an important role in metabolic homeostasis and may contribute to the development and progression of overweight and obesity through interactions with host metabolism, intestinal barrier function, immune responses, and microbial-derived metabolites.
Read full original descriptionShow less
This randomized, double-blind, placebo-controlled clinical trial will evaluate whether daily supplementation with a chemically characterized wild thyme (Thymus serpyllum L.) extract for 12 weeks can improve body weight and obesity- and overweight-related anthropometric, metabolic, and inflammatory parameters and modulate the gut microbiome in adults with overweight or obesity. Participants will be randomly assigned in a 1:1 ratio to receive either wild thyme extract or a matching placebo. The primary objective is to evaluate the effect of the intervention on change in body weight after 12 weeks of treatment. Secondary objectives include evaluating changes in body composition, waist circumference, metabolic parameters, inflammatory biomarkers, and intestinal microbiome composition. The study will also investigate whether baseline gut microbiome characteristics or changes in the gut microbiome are associated with the clinical response to treatment, with the aim of identifying potential microbiome-based biomarkers of response. By targeting individuals across the spectrum from overweight to obesity, this study aims to explore whether early intervention in excess adiposity may provide an opportunity to improve metabolic health and potentially reduce progression toward more severe obesity and associated complications.
The 2 groups in the trial
- Wild Thyme ExtractTreatment being tested
Participants assigned to the experimental arm will receive a chemically characterized wild thyme (Thymus serpyllum L.) extract at a total daily dose of 600 mg, administered orally in capsule form once daily for 12 weeks.
- PlaceboPlacebo, for comparison
Participants assigned to the placebo arm will receive matching placebo capsules containing microcrystalline cellulose at an equivalent daily administration schedule for 12 weeks.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Randomized, Double-Blind, Placebo-Controlled Pilot Study to Evaluate the Effects of a Chemically Characterized Wild Thyme (Thymus Serpyllum L.) Extract on Body Weight, Metabolic Health, Inflammation, and the Gut Microbiome in Adults With Overweight or Obesity
- Fit questions
- Built from NCT07939425, who can take part
- Record updated
- 16 November 2026